KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Inventory (2016 - 2024)

Nektar Therapeutics has reported Inventory over the past 15 years, most recently at $14.5 million for Q2 2024.

  • Quarterly results put Inventory at $14.5 million for Q2 2024, down 30.08% from a year ago — trailing twelve months through Jun 2024 was $14.5 million (down 30.08% YoY), and the annual figure for FY2023 was $16.1 million, down 16.15%.
  • Inventory for Q2 2024 was $14.5 million at Nektar Therapeutics, down from $16.2 million in the prior quarter.
  • Over the last five years, Inventory for NKTR hit a ceiling of $20.7 million in Q2 2023 and a floor of $12.6 million in Q2 2020.
  • Median Inventory over the past 5 years was $15.6 million (2021), compared with a mean of $16.2 million.
  • Biggest five-year swings in Inventory: surged 31.58% in 2023 and later plummeted 30.08% in 2024.
  • Nektar Therapeutics' Inventory stood at $15.3 million in 2020, then rose by 3.33% to $15.8 million in 2021, then rose by 21.52% to $19.2 million in 2022, then dropped by 16.15% to $16.1 million in 2023, then dropped by 10.16% to $14.5 million in 2024.
  • The last three reported values for Inventory were $14.5 million (Q2 2024), $16.2 million (Q1 2024), and $16.1 million (Q4 2023) per Business Quant data.